BHVN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BHVN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-07-01), Biohaven's share price is $14.11. Biohaven's GF Value is $0.00. Therefore, Biohaven's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes Biohaven is Not Valued.
The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.
To calculate this value, GuruFocus follows these steps:
GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.
Biohaven (NYSE:BHVN) GF Value Explanation
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:
Posssible Evaluations | All-in-One Screener Examples (1) |
Possible Value Trap, Think Twice | Predictable Companies that possibly be Value Traps |
Significantly Overvalued | Predictable Companies which are Significantly Overvalued |
Modestly Overvalued | Predictable Companies which are Modestly Overvalued |
Fairly Valued | Predictable High Quality Companies which are Fairly Valued |
Modestly Undervalued (2) | Predictable High Quality Companies which are Modestly Undervalued |
Significantly Undervalued (2) | Predictable High Quality Companies which are Significantly Undervalued |
(1) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.
(2) A sufficient margin of safety exists only when the stock is undervalued.
Possible Value Trap, Think Twice companies are those that appear significantly undervalued based on their Price-to-GF-Value ratio, but whose fundamentals show signs of weakness.
Indicators that a company may be a value trap include:
* Deteriorating Financial Health: A low Altman Z-scores indicates a higher risk of bankruptcy, or a low Piotroski F-Score.
* Earnings Manipulation: A high Beneish M-score indicates potential earnings manipulation, raising concerns about the reliability of reported financials.
* Stagnant or Declining Growth: Lack of revenue or earnings growth, or a recent slowdown, may signal limited future prospects.
Investors should conduct thorough due diligence, examining financial statements and growth indicators, to avoid falling into value traps.
Biohaven's Price-to-GF-Value for today is calculated as
Price-to-GF-Value | = | Share Price | / | GF Value |
= | 14.11 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Biohaven's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.
John W Childs | director | 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199 |
Vlad Coric | director, officer: Chief Executive Officer | C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
Gregory Bailey | director | 4 A CHESHAM STREET, LONDON X0 SW1X8DT |
Bruce Car | officer: Chief Scientific Officer | AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Irina Antonijevic | director | 215 CHURCH STREET, NEW HAVEN CT 06510 |
Matthew Buten | officer: Chief Financial Officer | 215 CHURCH STREET, NEW HAVEN CT 06510 |
George C. Clark | officer: VP, Chief Accounting Officer | 215 CHURCH STREET, NEW HAVEN CT 06510 |
Julia P Gregory | director | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Robert J Hugin | director | C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054 |
Michael Thomas Heffernan | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Kimberly Gentile | officer: SVP, Clinical Operations | C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510 |
Kishan Mehta | director | 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019 |
Biohaven Pharmaceutical Holding Co Ltd. | 10 percent owner | 215 CHURCH STREET, NEW HAVEN CT 06510 |
From GuruFocus
By GuruFocus News • 05-28-2025
By GuruFocus News • 05-19-2025
By GuruFocus News • 05-15-2025
By GuruFocus News • 05-29-2025
By GuruFocus News • 05-15-2025
By GuruFocus News • 05-13-2025
By GuruFocus News • 05-14-2025
By GuruFocus News • 05-29-2025
By GuruFocus News • 05-15-2025
By GuruFocus News • 05-19-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.